132 related articles for article (PubMed ID: 35225472)
1. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
[TBL] [Abstract][Full Text] [Related]
2. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
[TBL] [Abstract][Full Text] [Related]
3. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
[TBL] [Abstract][Full Text] [Related]
4. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy.
Noh OK; Oh SY; Kim YB; Suh KW
World J Surg; 2017 Nov; 41(11):2898-2905. PubMed ID: 28707088
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.
Lu CY; Tsai HL; Uen YH; Hu HM; Chen CW; Cheng TL; Lin SR; Wang JY
Br J Cancer; 2013 Mar; 108(4):791-7. PubMed ID: 23422758
[TBL] [Abstract][Full Text] [Related]
7. [Predicting value of dynamic alteration of blood neutrophil/lymphocyte ratio on recurrence-free survival in patients with advanced colon cancer after operation and chemotherapy].
Li J; Jia YB; Cai CN; Guan XD; Li PP; Xie YY; Zhang BM
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Nov; 15(11):1171-4. PubMed ID: 23172532
[TBL] [Abstract][Full Text] [Related]
8. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
Cha YJ; Park EJ; Baik SH; Lee KY; Kang J
Sci Rep; 2019 Aug; 9(1):11617. PubMed ID: 31406179
[TBL] [Abstract][Full Text] [Related]
10. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
[TBL] [Abstract][Full Text] [Related]
11. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
13. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
15. CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
Rothé F; Maetens M; Rouas G; Paesmans M; Van den Eynde M; Van Laethem JL; Vergauwe P; Deboever G; Bareche Y; Vandeputte C; Ignatiadis M; Hendlisz A
BMC Cancer; 2019 Apr; 19(1):304. PubMed ID: 30943928
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
17. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
18. Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
Ji WB; Hong KD; Kim JS; Joung SY; Um JW; Min BW
Chemotherapy; 2018; 63(1):8-12. PubMed ID: 29130943
[TBL] [Abstract][Full Text] [Related]
19. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
